A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled, Multi-region Study to Evaluate the Efficacy, Safety, and Immunogenicity of Inactivated EV71 Vaccine Produced in Vero Cells With Adjuvant in Infants and Children
Latest Information Update: 21 Apr 2022
At a glance
- Drugs Enterovirus A vaccine (Primary)
- Indications Enterovirus A infections
- Focus Registrational; Therapeutic Use
- Sponsors Medigen Biotechnology Corporation
- 13 Apr 2022 Primary endpoint number of Laboratory Confirmed EV71-Associated Disease has been met, according to results published in the Lancet..
- 13 Apr 2022 Status changed from active, no longer recruiting to completed according to results published in the Lancet.
- 13 Apr 2022 Results published in the Lancet